JPS625404B2 - - Google Patents

Info

Publication number
JPS625404B2
JPS625404B2 JP55078466A JP7846680A JPS625404B2 JP S625404 B2 JPS625404 B2 JP S625404B2 JP 55078466 A JP55078466 A JP 55078466A JP 7846680 A JP7846680 A JP 7846680A JP S625404 B2 JPS625404 B2 JP S625404B2
Authority
JP
Japan
Prior art keywords
brain
oxo
compounds according
properties
pyrrolidinyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
JP55078466A
Other languages
English (en)
Japanese (ja)
Other versions
JPS562960A (en
Inventor
Betsuingu Hansu
Biideruman Yurugen
Materune Karushuten
Noizeru Horukeru
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
A Natterman und Cie GmbH
Original Assignee
A Natterman und Cie GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by A Natterman und Cie GmbH filed Critical A Natterman und Cie GmbH
Publication of JPS562960A publication Critical patent/JPS562960A/ja
Publication of JPS625404B2 publication Critical patent/JPS625404B2/ja
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP7846680A 1979-06-13 1980-06-12 Pyrrolidinylalkylcarboxylic acid amide derivative* its manufacture and medicinal composition Granted JPS562960A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19792923975 DE2923975A1 (de) 1979-06-13 1979-06-13 Pyrrolidinone, verfahren zu deren herstellung und diese enthaltende arzneimittel

Publications (2)

Publication Number Publication Date
JPS562960A JPS562960A (en) 1981-01-13
JPS625404B2 true JPS625404B2 (enExample) 1987-02-04

Family

ID=6073167

Family Applications (2)

Application Number Title Priority Date Filing Date
JP7846680A Granted JPS562960A (en) 1979-06-13 1980-06-12 Pyrrolidinylalkylcarboxylic acid amide derivative* its manufacture and medicinal composition
JP61061971A Granted JPS61280470A (ja) 1979-06-13 1986-03-19 ピロリジニルアルキルカルボン酸アミド誘導体およびその製造方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP61061971A Granted JPS61280470A (ja) 1979-06-13 1986-03-19 ピロリジニルアルキルカルボン酸アミド誘導体およびその製造方法

Country Status (2)

Country Link
JP (2) JPS562960A (enExample)
DE (1) DE2923975A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2515179A1 (fr) * 1981-07-24 1983-04-29 Hoffmann La Roche Derives de pyrrolidine, leur procede de preparation, les intermediaires pour leur synthese et leur application therapeutique
CH647234A5 (en) * 1981-07-24 1985-01-15 Hoffmann La Roche Pyrrolidine derivatives
DE3326724A1 (de) * 1983-07-25 1985-02-07 Boehringer Ingelheim KG, 6507 Ingelheim In 1-stellung substituierte 4-hydroxymethyl-pyrrolidinone, verfahren zu ihrer herstellung, pharmazeutische zusammensetzungen und zwischenprodukte
DE3336024A1 (de) * 1983-10-04 1985-04-18 Boehringer Ingelheim KG, 6507 Ingelheim 4-amino-l-benzyl-pyrrolidinone und ihre saeureadditionssalze, verfahren zu ihrer herstellung und arzneimittel
DE3813416A1 (de) * 1988-04-21 1989-11-02 Hoechst Ag 3,4-dihydroxypyrrolidin-2-on-derivate, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung sowie die bei der herstellung anfallenden neuen zwischenprodukte
CH680293A5 (enExample) * 1990-06-26 1992-07-31 Lonza Ag
ATE224873T1 (de) * 1995-03-23 2002-10-15 Daiichi Seiyaku Co Wasserfreie kristalle
EP0953356A4 (en) 1996-10-01 2002-04-17 Daiichi Seiyaku Co MITOCHONDRIAL MEMBRANE STABILIZER
DE69823851D1 (de) * 1997-07-15 2004-06-17 Daiichi Seiyaku Co Nefiracetam zur prophylaxe und behandlung von propofol verursachtem gedächtnisschwund
US6423739B1 (en) 2000-02-23 2002-07-23 Daiichi Pharmaceutical Co., Ltd. Method for aiding cerebral recovery following neurodegeneration
MXPA03005889A (es) 2000-12-28 2005-02-14 Daiichi Seiyaku Co Agente para tratamiento terapeutico y profilactico del dolor neuropatico.

Also Published As

Publication number Publication date
JPS562960A (en) 1981-01-13
DE2923975C2 (enExample) 1988-07-21
JPH0346466B2 (enExample) 1991-07-16
JPS61280470A (ja) 1986-12-11
DE2923975A1 (de) 1980-12-18

Similar Documents

Publication Publication Date Title
JPS625404B2 (enExample)
Czura et al. Neural inhibition of inflammation: the cholinergic anti-inflammatory pathway
DE60210782T2 (de) Glukokinase beeinflussende verbindungen
EP0131226A2 (de) Derivate der 2-Azabicyclo(3.1.0)hexan-3-carbonsäure, Verfahren zu ihrer Herstellung, diese enthaltende Mittel und deren Verwendung sowie 2-Azabicyclo(3.1.0)hexan-Derivate als Zwischenprodukte und Verfahren zu deren Herstellung
DE1183508B (de) Verfahren zur Herstellung von N-Allyl-14-hydroxydihydronormorphinon und seinen Salzen
PT1830869E (pt) Método de tratamento ou profilaxia
DE69330754T2 (de) 2,5-DIOXO-2,5-DIHYDRO-1H-BENZ[b]AZEPINE ALS NMDA REZEPTOR ANTAGONISTEN
KR100308097B1 (ko) 1-아미노아세트아미도피롤1-아미노아세트아미도-2-(치환된)피롤및관련화합물과이를함유하는약제학적조성물
CN106459021B (zh) 用于治疗神经退行性疾病的组合物和方法
DE602004006268T2 (de) Substituierte diketopiperazine und deren verwendung als oxytocynantagonisten
DE2727047A1 (de) Indol-derivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate
DE69122858T2 (de) Therapeutische benzazepin verbindungen
FR2512019A1 (fr) Derives de carbostyryle, leurs procedes de preparation et composition therapeutique les contenant
DE1493561C3 (de) Peptid mit Antischockwirkung und Verfahren zu seiner Herstellung
DE69004989T2 (de) Indolderivate.
EP0286927A2 (de) Neue Pyrrolidin-2-(1,3-dicarbonyl)-Derivate, Verfahren zu ihrer Herstellung, sie enthaltende Mittel sowie deren Verwendung
US4321194A (en) N-Substituted aziridine-2-carboxylic acid derivatives for immuno stimulation
US4128555A (en) 3-Phenoxypyridine monosulfate and a method for its production
DE69020752T2 (de) Peptide, die eine reninhemmende Aktivität besitzen, deren Herstellung und Verwendung.
WO1990011080A1 (en) Drug for improving brain function
EP0279283A2 (de) Pyridazinonderivate
DE2924011C2 (de) Pyrrolidin-(2)-on-(1)-ylessigsäure-2,6,-dimethylanilid, Verfahren zur Herstellung und Arzneimittel, welche diese Verbindung enthalten
DE2557220A1 (de) N-substituierte spirolactame
DE2064061C3 (de) Neue tuberkulostatisch wirkende alpha-Aminoxycarbonsäurederivate, Verfahren zur Herstellung derselben und diese enthaltende pharmazeutische Präparate
DE2213028A1 (de) Homocysteinthiolacton-Abkömmlinge und Verfahren zu deren Herstellung